Protalix BioTherapeutics CEO buys 56,000 shares at $1.81

Protalix BioTherapeutics, Inc. insider transaction: the company’s President and CEO, who also serves as a director, reported buying 56,000 shares of common stock of Protalix BioTherapeutics, Inc. on 12/19/2025 at a price of $1.81 per share.

Accepted by SEC EDGAR 12/23/2025 - 07:25 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. insider transaction: the company’s President and CEO, who also serves as a director, reported buying 56,000 shares of common stock of Protalix BioTherapeutics, Inc. on 12/19/2025 at a price of $1.81 per share. After this purchase, the insider directly owns 188,516 common shares and indirectly holds an additional 2,344,418 shares through a trust. The filing notes that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the company’s plan must be registered in the name of a trustee.

Insider Trade Summary

Net Buyer: 56,000 shares

Net Buy 1 txn

Insider Bashan Dror

Role PRESIDENT AND CEO

Bought 56,000 shs ($101K)

Increase in Position 42.3%

Type	Security	Shares	Price	Value
Purchase	Common Stock	56,000	$1.81	$101K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 188,516 shares (Direct); Common Stock — 2,344,418 shares (Indirect, By Trust)

Holdings Before and After: Common Stock, 132,516 to 188,516 shares (Direct)

Footnotes (1)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction was reported for Protalix BioTherapeutics (PLX)?

The President and CEO, who is also a director, reported purchasing 56,000 shares of Protalix BioTherapeutics common stock on 12/19/2025 at $1.81 per share.

How many Protalix BioTherapeutics (PLX) shares does the insider own after the transaction?

Following the reported transaction, the insider directly owns 188,516 common shares and indirectly holds 2,344,418 shares through a trust.

What is the insider’s role at Protalix BioTherapeutics (PLX)?

The reporting person is a director and serves as President and CEO of Protalix BioTherapeutics, Inc.

On what date did the Protalix BioTherapeutics (PLX) insider trade occur?

The earliest transaction date reported is 12/19/2025.

What does the trust holding Protalix BioTherapeutics (PLX) shares represent?

The filing shows 2,344,418 shares held indirectly by a trust and explains that, to obtain certain tax benefits under Section 102 of the Israeli Tax Ordinance, plan-related securities must be registered in a trustee’s name.

Was the reported Protalix BioTherapeutics (PLX) transaction a purchase or a sale?

The Form 4 reports a purchase of 56,000 shares of Protalix BioTherapeutics common stock at $1.81 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bashan Dror

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL L3 2161401

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/19/2025		P		56,000	A	$1.81	188,516	D
Common Stock								2,344,418	I	By Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

	/s/ Joseph R. Magnas, Attorney-in-Fact	12/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.